Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

This will be a single-center, cross-over study evaluating the effect of Omnaris Nasal Spray 200 mcg QD and Alvesco Inhalation Aerosol 80 BID versus Beconase AQ Nasal Spray 168 mcg BID and QVAR Inhalation Aerosol 40 mcg BID versus Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID on short term growth in pediatric subjects with mild asthma and allergic rhinitis. During the course of the study, subjects will be seen on a weekly basis and lower leg length will be measured using knemometry. Knemometry is a non invasive technique for measuring short-term lower leg growth in children and is currently the method of choice in growth studies of short duration. During the run-in and wash-out periods, subjects will not be treated with any medications or placebos. During the active treatment periods, subjects will be treated with Omnaris Nasal Spray 200 mcg QD and Alvesco Inhalation Aerosol 80 BID or Beconase AQ Nasal Spray 168 mcg BID and QVAR Inhalation Aerosol 40 mcg BID, or Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID. Eligible subjects will be randomized into the study which will contain one run-in period (Period 1), 3 active treatment periods (Periods 2, 4 and 6) and 2 washout periods (Periods 3 and 5). Each period will be of 3 weeks duration and the entire study duration will be 18 weeks. Subjects will be seen on a weekly basis for 18 weeks and at each visit, lower leg length will be measured using knemometry.

Inclusion criteria

• Subjects will include females and males 6 to 15 years of age.
• All subjects must have a history of physician diagnosed mild asthma and allergic rhinitis as documented by PCP medical record or detailed history by study investigator.
• All subjects must have a height within normal limits (5th to 95th percentile) and no history of abnormal growth as assessed by medical history.
• Subjects may be on current treatment with montelukast as this drug does not affect growth. If a subject is on montelukast at screening/baseline, they will remain on a stable dose throughout the study.
• Subjects must be willing to comply with study requirements.

Exclusion criteria

• Subjects will be excluded if they have asthma greater than mild persistent severity as defined by NHLBI guidelines.

2 Subjects will be excluded if they used any systemic steroids within the past 60 days.

• Subjects will be excluded if they had more than one burst of systemic steroids within the past year.

• Subjects will be excluded if their baseline FEV1 is < 80% predicted. 5. Subjects will be excluded if they have any other serious systemic disease other than asthma.

• Subjects will be excluded if they have taken any medication known to affect growth i.e. ADHD medications within the past 60 days 7. Subjects will be excluded if they have a history of allergy to any of the study medications.

• Subjects will be excluded if they have active chickenpox or measles or recent exposure to chickenpox or measles.

• Subjects will be excluded if they have any history of tuberculosis of the respiratory tract.

• Subjects will be excluded if they have any active fungal, bacterial, viral or parasitic infections.

• Subjects will be excluded if they have any history of herpes simplex infection of the eye.

• Subjects will be excluded if they have taken any immunosuppressive drugs within the past 2 months.

• Subjects will be excluded if they have any history of Churg-Strauss syndrome or other eosinophilic disorders.

• Subjects will be excluded if an investigator deems they have any mental or development health issues, such as autism, moderate to severe mental retardation or severe ADHD, that interferes with their ability to complete the knemometry measurements.

• Subjects will be excluded if an investigator deems they have any physical issues, such as inability to sit independently or amputation of lower leg, that interferes with their ability to complete the knemometry measurements.